Acuff Samuel F, Strickland Justin C
Recovery Research Institute, Massachusetts General Hospital and Harvard Medical School, 151 Merrimac Street, Boston, MA 02114, USA.
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA.
Drug Alcohol Depend. 2025 Jan 1;266:112521. doi: 10.1016/j.drugalcdep.2024.112521. Epub 2024 Nov 28.
Despite increases in the availability, potency, and consumption of cannabis, epidemiological data suggest decreases in the prevalence of cannabis use disorder (CUD) in some groups. Understanding mechanisms for these changes may help improve diagnostic tools for identifying disordered use. This analysis evaluates changes in CUD compared to a substance with comparably stable social and environmental context (alcohol use disorder [AUD]) as well as treatment engagement and need from 2002 to 2019.
Data were from the National Survey on Drug Use and Health. Outcomes included CUD and AUD symptoms, treatment engagement, and perceived need. Temporal trends and average annual rate of change [AARC] were computed.
Between 2002 and 2019, daily cannabis use prevalence increased by 94 % (AARC=11.68 %), whereas CUD prevalence among those using cannabis daily reduced by 47.9 % (AARC=-10.30 %). Daily alcohol use prevalence decreased by 10.86 % (AARC=-1.90 %), and AUD prevalence among those using alcohol daily reduced by 3.9 % (AARC=-0.67 %). Prevalence of individual 12-month CUD criteria among those using cannabis daily decreased (-13.4 to -59.6 % change; AARC = -2.4 % to -14 %). Among those using cannabis daily, trends in prevalence of individual AUD criteria varied, with some criteria increasing in prevalence and others decreasing (-30.2-24.6 % change; AARC = -5.82-3.7 %). Treatment engagement and perceived need decreased for cannabis, whereas treatment engagement increased and perceived need decreased for alcohol.
These results suggest that CUD and AUD criteria may be determined within the cultural context dictating the definition of harm which has changed for cannabis, but not alcohol, from 2002 to 2019.
尽管大麻的可得性、效力和消费量有所增加,但流行病学数据表明,某些群体中大麻使用障碍(CUD)的患病率有所下降。了解这些变化的机制可能有助于改进用于识别无序使用的诊断工具。本分析评估了2002年至2019年期间CUD与具有相对稳定社会和环境背景的物质(酒精使用障碍[AUD])相比的变化,以及治疗参与情况和需求。
数据来自全国药物使用和健康调查。结果包括CUD和AUD症状、治疗参与情况以及感知需求。计算了时间趋势和平均年变化率[AARC]。
在2002年至2019年期间,每日大麻使用患病率增加了94%(AARC=11.68%),而每日使用大麻者中的CUD患病率下降了47.9%(AARC=-10.30%)。每日酒精使用患病率下降了10.86%(AARC=-1.90%),每日饮酒者中的AUD患病率下降了3.9%(AARC=-0.67%)。每日使用大麻者中个体12个月CUD标准的患病率下降(变化-13.4%至-59.6%;AARC=-2.4%至-14%)。在每日使用大麻者中,个体AUD标准患病率的趋势各不相同,一些标准患病率上升,另一些标准患病率下降(变化-30.2%-24.6%;AARC=-5.82%-3.7%)。大麻的治疗参与情况和感知需求下降,而酒精的治疗参与情况增加且感知需求下降。
这些结果表明,CUD和AUD标准可能是在文化背景中确定的,该文化背景决定了危害的定义,从2002年到2019年,大麻的危害定义发生了变化,而酒精的没有。